EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Randomized crossover comparison of two teriparatide self-injection regimens for primary osteoporosis: final report of the Japanese Osteoporosis Intervention Trial 06 (JOINT-06)

Sakae Tanaka, Yukari Uemura, Shiro Tanaka, Yasuhiro Takeuchi, Naoto Endo, Junichi Takada, Satoshi Ikeda, Jun Iwamoto, Nobukazu Okimoto, Satoshi Soen

Journal of Bone and Mineral Metabolism · 2025-11 · 43 (6) · 640-648

DOI: 10.1007/s00774-025-01631-w ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Bone and Mineral Metabolism, online erschienen am 03.09.2025. Verfasst von Sakae Tanaka und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. tanakas-ort@h.u-toky…. Hauptthemen laut MEDLINE: Teriparatide, Osteoporosis, Bone Density Conservation Agents, Osteoporosis, Postmenopausal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Public Health Research Foundation, Asahi Kasei Pharma Corp., The University of Tokyo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Although bone anabolic agents such as teriparatide are effective for osteoporosis, satisfaction and adherence may vary by regimen. This multicenter study assessed long-term satisfaction, persistence, efficacy, and safety in postmenopausal women with primary osteoporosis treated with alternating daily and twice-weekly teriparatide over 52 weeks, followed by a final free-choice treatment period. Materials and methods In a randomized, open-label, crossover study, 358 postmenopausal women at high risk for fracture were assigned to receive once-daily (20 µg) or twice-weekly (28.2 µg) subcutaneous teriparatide for 26 weeks, then crossed over to the alternative regimen for another 26 weeks. Afterwards, 233 patients entered a 52-week free-choice period under their preferred regimen.

Results

Among the 233 patients entering the free-choice period, 162 chose twice-weekly and 71 chose daily teriparatide. Persistence at 104 weeks was 90.1% for twice-weekly and 88.7% for daily groups (p = 0.749). Overall and treatment satisfaction between groups did not differ significantly at 104 weeks (p > 0.05). Fracture incidence was low and similar (2.8% vs. 1.2%, p = 0.758). Patients in both groups showed significant increases in bone mineral density at L2–L4 and the femoral neck (p < 0.05). Adverse events were infrequent and non-severe.

Conclusions

Patient satisfaction and efficacy were maintained with both teriparatide regimens over 104 weeks, and persistence improved during the patient-choice phase. Supporting patient preference may improve adherence to osteoporosis medications. Clinical trial registration Japan Registry of Clinical Trials ID: jRCTs031210187.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TeriparatideOsteoporosisBone Density Conservation AgentsOsteoporosis, PostmenopausalHumansFemaleAgedMiddle AgedCross-Over StudiesJapanPatient SatisfactionEast Asian People

Stichwörter der Autor:innen

Crossover comparisonOnce-daily vs. twice-weekly self-injectionOsteoporosisPatient satisfactionTeriparatide

Substanzen

TeriparatideBone Density Conservation Agents

Autor:innen und Institutionen

  • Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. tanakas-ort@h.u-tokyo.ac.jp.
  • Biostatistics Section, Department of Data Science, Center for Clinical Sciences, Japan Institute for Health Security, Toyama, Shinjuku-ku, Tokyo, Japan.
  • Department of Clinical Biostatistics, Graduate School of Medicine, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto, Japan.
  • Toranomon Hospital Kajigaya, Takatsu-ku, Kawasaki, Japan.
  • Department of Orthopedic Surgery, Saiseikai Niigata Kenoh Kikan Hospital, Kamisugoro, Sanjo, Niigata, Japan.
  • Osteoporosis Center, Sapporo Maruyama Orthopaedic Hospital, Chuo-ku, Sapporo, Hokkaido, Japan.

Förderung

  • Public Health Research Foundation
  • Asahi Kasei Pharma Corp.
  • The University of Tokyo

Zitieren

APA

Tanaka, S., Uemura, Y., Tanaka, S., Takeuchi, Y., Endo, N., Takada, J., Ikeda, S., Iwamoto, J., Okimoto, N., & Soen, S. (2025). Randomized crossover comparison of two teriparatide self-injection regimens for primary osteoporosis: final report of the Japanese Osteoporosis Intervention Trial 06 (JOINT-06). Journal of Bone and Mineral Metabolism, 43(6), 640-648. https://doi.org/10.1007/s00774-025-01631-w

Vancouver

Tanaka S, Uemura Y, Tanaka S, Takeuchi Y, Endo N, Takada J, et al. Randomized crossover comparison of two teriparatide self-injection regimens for primary osteoporosis: final report of the Japanese Osteoporosis Intervention Trial 06 (JOINT-06). Journal of Bone and Mineral Metabolism. 2025;43(6):640-648. doi:10.1007/s00774-025-01631-w

BibTeX
@article{Tanaka2025,
  author = {Tanaka, Sakae and Uemura, Yukari and Tanaka, Shiro and Takeuchi, Yasuhiro and Endo, Naoto and Takada, Junichi and Ikeda, Satoshi and Iwamoto, Jun and Okimoto, Nobukazu and Soen, Satoshi},
  title = {Randomized crossover comparison of two teriparatide self-injection regimens for primary osteoporosis: final report of the Japanese Osteoporosis Intervention Trial 06 (JOINT-06)},
  journal = {Journal of Bone and Mineral Metabolism},
  year = {2025},
  volume = {43},
  number = {6},
  pages = {640--648},
  doi = {10.1007/s00774-025-01631-w}
}
Kostenlos starten →